Profile data is unavailable for this security.
About the company
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
- Revenue in INR (TTM)3.05bn
- Net income in INR188.89m
- Incorporated1987
- Employees693.00
- LocationHester Biosciences LtdPushpak 1st FloorMotilal Hirabhai Road, Panchvati CircleAHMEDABAD 380006IndiaIND
- Phone+91 7 926445107
- Fax+91 7 926445105
- Websitehttps://www.hester.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vimta Labs Ltd | 3.18bn | 410.09m | 10.54bn | 1.37k | 26.07 | 3.30 | 14.02 | 3.31 | 18.24 | 18.24 | 141.64 | 144.20 | 0.8349 | 3.23 | 3.81 | -- | 10.76 | 10.53 | 12.60 | 12.77 | 76.02 | 73.65 | 12.89 | 12.16 | 2.46 | 24.79 | 0.0566 | 11.15 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 10.65bn | 38.00 | 113.08 | 40.98 | 118.56 | 23.65 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 10.69bn | 763.00 | 14.42 | 1.11 | 9.91 | 1.39 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Syncom Formulations (India) Ltd | 2.63bn | 253.14m | 10.86bn | 799.00 | 33.97 | 3.77 | 36.15 | 4.12 | 0.34 | 0.34 | 3.56 | 3.07 | 0.6732 | 7.42 | 2.95 | -- | 6.47 | 7.50 | 9.00 | 10.23 | 40.44 | 34.59 | 9.61 | 9.38 | 2.38 | 5.57 | 0.201 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Kopran Ltd | 6.15bn | 509.56m | 11.28bn | 394.00 | 22.29 | 2.30 | 17.67 | 1.84 | 10.50 | 10.50 | 126.95 | 101.90 | 0.8824 | 2.99 | 3.28 | -- | 7.32 | 8.47 | 10.22 | 12.23 | 34.60 | 34.18 | 8.29 | 8.89 | 1.44 | 43.23 | 0.168 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 11.34bn | 1.70k | 12.15 | 1.91 | 10.91 | 1.95 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Beta Drugs Ltd | 2.56bn | 347.57m | 11.44bn | 315.00 | 32.92 | 8.06 | 24.99 | 4.47 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Zota Health Care Ltd | 1.80bn | -143.48m | 12.19bn | 338.00 | -- | 13.20 | 212.25 | 6.75 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Windlas Biotech Ltd | 6.31bn | 581.87m | 13.25bn | 1.05k | 22.80 | 2.94 | 18.50 | 2.10 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Ngl Fine Chem Ltd | 3.39bn | 413.43m | 14.00bn | 343.00 | 33.87 | 5.33 | 26.44 | 4.13 | 66.92 | 66.92 | 548.61 | 425.11 | 1.05 | 4.51 | 4.36 | -- | 12.87 | 15.06 | 16.61 | 19.58 | 53.18 | 46.79 | 12.20 | 13.15 | 1.96 | 30.64 | 0.1218 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Hester Biosciences Ltd | 3.05bn | 188.89m | 14.64bn | 693.00 | 69.15 | 5.02 | 38.19 | 4.81 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| SMS Pharmaceuticals Ltd | 7.09bn | 498.26m | 16.05bn | 1.10k | 32.20 | 2.99 | 19.89 | 2.26 | 5.89 | 5.89 | 83.84 | 63.36 | 0.7413 | 2.18 | 3.69 | -- | 5.14 | 5.43 | 7.41 | 7.33 | 29.83 | 32.67 | 6.94 | 7.87 | 0.905 | 3.63 | 0.3436 | 6.59 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Themis Medicare Ltd | 3.82bn | 435.24m | 18.74bn | 996.00 | 43.13 | 4.96 | 33.60 | 4.91 | 4.72 | 4.72 | 41.41 | 41.03 | 0.7067 | 1.96 | 2.36 | -- | 8.06 | 11.12 | 11.07 | 16.46 | 64.19 | 61.49 | 11.40 | 14.96 | 1.44 | -- | 0.2023 | 8.28 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Solara Active Pharma Sciences Ltd | 13.26bn | -5.67bn | 18.98bn | 2.36k | -- | 1.65 | -- | 1.43 | -145.25 | -145.25 | 339.41 | 239.08 | 0.505 | 1.75 | 2.99 | -- | -21.60 | -2.44 | -39.08 | -3.84 | 39.28 | 43.38 | -42.77 | -4.49 | 0.3549 | -1.89 | 0.5192 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
Data as of Jun 10 2024. Currency figures normalised to Hester Biosciences Ltd's reporting currency: Indian Rupee INR
0.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 27.97k | 0.33% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 3.28k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 335.00 | 0.00% |
| DFA Australia Ltd.as of 31 Dec 2023 | 127.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 51.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
